Cargando…
Human umbilical cord mesenchymal stem cells ameliorate skin fibrosis development in a mouse model of bleomycin-induced systemic sclerosis
Mesenchymal stem cell (MSC) infusion has become a novel therapeutic strategy for complex autoimmune diseases; however, few detailed studies have been performed to investigate the benefit and mechanism of MSC treatment on systemic sclerosis (SSc). The present study aimed to evaluate the therapeutic e...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664606/ https://www.ncbi.nlm.nih.gov/pubmed/33199983 http://dx.doi.org/10.3892/etm.2020.9387 |
_version_ | 1783609866019930112 |
---|---|
author | Yang, Yuan Zhu, Shuai Li, Yanhong Lu, Qian Zhang, Qiuyi Su, Linchong Zhang, Qiuping Zhao, Yi Luo, Yubin Liu, Yi |
author_facet | Yang, Yuan Zhu, Shuai Li, Yanhong Lu, Qian Zhang, Qiuyi Su, Linchong Zhang, Qiuping Zhao, Yi Luo, Yubin Liu, Yi |
author_sort | Yang, Yuan |
collection | PubMed |
description | Mesenchymal stem cell (MSC) infusion has become a novel therapeutic strategy for complex autoimmune diseases; however, few detailed studies have been performed to investigate the benefit and mechanism of MSC treatment on systemic sclerosis (SSc). The present study aimed to evaluate the therapeutic effect of human umbilical cord derived-MSCs (UC-MSCs) on bleomycin-induced SSc in mice and explore the potential underlying mechanism. The murine SSc model was established by daily subcutaneous injection of bleomycin for 4 weeks, followed with two UC-MSC infusions every 7 days. Skin fibrosis was assessed by H&E and Masson staining. Flow cytometry was used to determine IL-17A, IFN-γ, tumor necrosis factor-β, IL-10 and IL-12 levels in serum samples and T cell subsets in murine spleen. Additionally, gene expression levels of cytokines and fibrosis markers in skin samples were measured by reverse transcription-quantitative PCR. Immunofluorescence staining was performed to track UC-MSC localization and lymphocyte cell infiltration in vivo. UC-MSC treatment exerted an anti-fibrotic role in bleomycin-induced SSc mice, as confirmed by histological improvement, decreased collagen synthesis, and reduced collagen-1α1, collagen-1α2, fibronectin-1 and α-smooth muscle actin gene expression levels. The results indicated that UC-MSC treatment only had a limited systematic effect on cytokine production in serum samples and T cell activation in the spleen. By contrast, T helper (Th)17 cell infiltration and activation in skin were efficiently inhibited after UC-MSC infusion, as evidenced by the decreased IL-17A and retinoic acid-related orphan receptor γt gene expression as well as IL-17A production. UC-MSC administration significantly ameliorated bleomycin-induced skin fibrosis and collagen formation primarily by eliminating local inflammation and Th17 cell activation in the skin; however, the systemic inhibitory effect of UM-MSCs on cytokines was less profound. |
format | Online Article Text |
id | pubmed-7664606 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-76646062020-11-15 Human umbilical cord mesenchymal stem cells ameliorate skin fibrosis development in a mouse model of bleomycin-induced systemic sclerosis Yang, Yuan Zhu, Shuai Li, Yanhong Lu, Qian Zhang, Qiuyi Su, Linchong Zhang, Qiuping Zhao, Yi Luo, Yubin Liu, Yi Exp Ther Med Articles Mesenchymal stem cell (MSC) infusion has become a novel therapeutic strategy for complex autoimmune diseases; however, few detailed studies have been performed to investigate the benefit and mechanism of MSC treatment on systemic sclerosis (SSc). The present study aimed to evaluate the therapeutic effect of human umbilical cord derived-MSCs (UC-MSCs) on bleomycin-induced SSc in mice and explore the potential underlying mechanism. The murine SSc model was established by daily subcutaneous injection of bleomycin for 4 weeks, followed with two UC-MSC infusions every 7 days. Skin fibrosis was assessed by H&E and Masson staining. Flow cytometry was used to determine IL-17A, IFN-γ, tumor necrosis factor-β, IL-10 and IL-12 levels in serum samples and T cell subsets in murine spleen. Additionally, gene expression levels of cytokines and fibrosis markers in skin samples were measured by reverse transcription-quantitative PCR. Immunofluorescence staining was performed to track UC-MSC localization and lymphocyte cell infiltration in vivo. UC-MSC treatment exerted an anti-fibrotic role in bleomycin-induced SSc mice, as confirmed by histological improvement, decreased collagen synthesis, and reduced collagen-1α1, collagen-1α2, fibronectin-1 and α-smooth muscle actin gene expression levels. The results indicated that UC-MSC treatment only had a limited systematic effect on cytokine production in serum samples and T cell activation in the spleen. By contrast, T helper (Th)17 cell infiltration and activation in skin were efficiently inhibited after UC-MSC infusion, as evidenced by the decreased IL-17A and retinoic acid-related orphan receptor γt gene expression as well as IL-17A production. UC-MSC administration significantly ameliorated bleomycin-induced skin fibrosis and collagen formation primarily by eliminating local inflammation and Th17 cell activation in the skin; however, the systemic inhibitory effect of UM-MSCs on cytokines was less profound. D.A. Spandidos 2020-12 2020-10-27 /pmc/articles/PMC7664606/ /pubmed/33199983 http://dx.doi.org/10.3892/etm.2020.9387 Text en Copyright: © Yang et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Yang, Yuan Zhu, Shuai Li, Yanhong Lu, Qian Zhang, Qiuyi Su, Linchong Zhang, Qiuping Zhao, Yi Luo, Yubin Liu, Yi Human umbilical cord mesenchymal stem cells ameliorate skin fibrosis development in a mouse model of bleomycin-induced systemic sclerosis |
title | Human umbilical cord mesenchymal stem cells ameliorate skin fibrosis development in a mouse model of bleomycin-induced systemic sclerosis |
title_full | Human umbilical cord mesenchymal stem cells ameliorate skin fibrosis development in a mouse model of bleomycin-induced systemic sclerosis |
title_fullStr | Human umbilical cord mesenchymal stem cells ameliorate skin fibrosis development in a mouse model of bleomycin-induced systemic sclerosis |
title_full_unstemmed | Human umbilical cord mesenchymal stem cells ameliorate skin fibrosis development in a mouse model of bleomycin-induced systemic sclerosis |
title_short | Human umbilical cord mesenchymal stem cells ameliorate skin fibrosis development in a mouse model of bleomycin-induced systemic sclerosis |
title_sort | human umbilical cord mesenchymal stem cells ameliorate skin fibrosis development in a mouse model of bleomycin-induced systemic sclerosis |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664606/ https://www.ncbi.nlm.nih.gov/pubmed/33199983 http://dx.doi.org/10.3892/etm.2020.9387 |
work_keys_str_mv | AT yangyuan humanumbilicalcordmesenchymalstemcellsameliorateskinfibrosisdevelopmentinamousemodelofbleomycininducedsystemicsclerosis AT zhushuai humanumbilicalcordmesenchymalstemcellsameliorateskinfibrosisdevelopmentinamousemodelofbleomycininducedsystemicsclerosis AT liyanhong humanumbilicalcordmesenchymalstemcellsameliorateskinfibrosisdevelopmentinamousemodelofbleomycininducedsystemicsclerosis AT luqian humanumbilicalcordmesenchymalstemcellsameliorateskinfibrosisdevelopmentinamousemodelofbleomycininducedsystemicsclerosis AT zhangqiuyi humanumbilicalcordmesenchymalstemcellsameliorateskinfibrosisdevelopmentinamousemodelofbleomycininducedsystemicsclerosis AT sulinchong humanumbilicalcordmesenchymalstemcellsameliorateskinfibrosisdevelopmentinamousemodelofbleomycininducedsystemicsclerosis AT zhangqiuping humanumbilicalcordmesenchymalstemcellsameliorateskinfibrosisdevelopmentinamousemodelofbleomycininducedsystemicsclerosis AT zhaoyi humanumbilicalcordmesenchymalstemcellsameliorateskinfibrosisdevelopmentinamousemodelofbleomycininducedsystemicsclerosis AT luoyubin humanumbilicalcordmesenchymalstemcellsameliorateskinfibrosisdevelopmentinamousemodelofbleomycininducedsystemicsclerosis AT liuyi humanumbilicalcordmesenchymalstemcellsameliorateskinfibrosisdevelopmentinamousemodelofbleomycininducedsystemicsclerosis |